10.17
price up icon1.80%   0.18
 
loading
Immunome Inc stock is traded at $10.17, with a volume of 616.84K. It is up +1.80% in the last 24 hours and down -7.29% over the past month. Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
See More
Previous Close:
$9.99
Open:
$10.17
24h Volume:
616.84K
Relative Volume:
0.80
Market Cap:
$634.78M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-3.0709
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
+8.42%
1M Performance:
-7.29%
6M Performance:
-23.59%
1Y Performance:
-24.67%
1-Day Range:
Value
$9.85
$10.52
1-Week Range:
Value
$9.50
$11.06
52-Week Range:
Value
$8.97
$30.96

Immunome Inc Stock (IMNM) Company Profile

Name
Name
Immunome Inc
Name
Phone
610-321-3700
Name
Address
18702 N. CREEK PARKWAY, BOTHELL
Name
Employee
105
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
IMNM's Discussions on Twitter

Compare IMNM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IMNM
Immunome Inc
10.17 634.78M 0 -106.81M -8.40M -3.3117
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-08-24 Initiated Stephens Overweight
May-31-24 Initiated Piper Sandler Overweight
Apr-30-24 Initiated JP Morgan Overweight
Apr-15-24 Initiated Guggenheim Buy
Jan-29-24 Initiated Leerink Partners Outperform
Dec-19-23 Initiated Wedbush Outperform
Oct-29-21 Initiated Cantor Fitzgerald Overweight
View All

Immunome Inc Stock (IMNM) Latest News

pulisher
Jan 19, 2025

Short Interest in Immunome, Inc. (NASDAQ:IMNM) Grows By 12.2% - MarketBeat

Jan 19, 2025
pulisher
Jan 17, 2025

Immunome (NASDAQ:IMNM) Shares Gap UpShould You Buy? - MarketBeat

Jan 17, 2025
pulisher
Jan 15, 2025

Immunome, Inc. (NASDAQ:IMNM) Receives $28.83 Consensus PT from Brokerages - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Analysts - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Immunome (NASDAQ:IMNM) Stock Price Down 7.1%Here's Why - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Immunome’s (IMNM) Outperform Rating Reaffirmed at Wedbush - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Immunome (NASDAQ:IMNM) Given "Outperform" Rating at Wedbush - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Immunome (NASDAQ:IMNM) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace

Jan 13, 2025
pulisher
Jan 13, 2025

Immunome Provides Pipeline Update in Advance of Presentation at the 43 - Business Wire

Jan 13, 2025
pulisher
Jan 13, 2025

Immunome, Inc. (NASDAQ:IMNM) Shares Purchased by Barclays PLC - Defense World

Jan 13, 2025
pulisher
Jan 12, 2025

Head to Head Comparison: Oculis (NASDAQ:OCS) vs. Immunome (NASDAQ:IMNM) - Defense World

Jan 12, 2025
pulisher
Jan 11, 2025

Head to Head Analysis: Immunome (NASDAQ:IMNM) vs. Bicara Therapeutics (NASDAQ:BCAX) - Defense World

Jan 11, 2025
pulisher
Jan 07, 2025

Hummingbird Bioscience Licenses Novel Antibodies to Immunome - The Korea Bizwire

Jan 07, 2025
pulisher
Jan 05, 2025

When the Price of (IMNM) Talks, People Listen - Stock Traders Daily

Jan 05, 2025
pulisher
Jan 02, 2025

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jan 02, 2025
pulisher
Jan 02, 2025

Immunome Awards Stock Options to Key New Hires in Strategic Talent Acquisition Move - StockTitan

Jan 02, 2025
pulisher
Jan 01, 2025

Immunome, Inc. (NASDAQ:IMNM) Sees Significant Drop in Short Interest - MarketBeat

Jan 01, 2025
pulisher
Dec 30, 2024

Geode Capital Management LLC Has $17.66 Million Stake in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Dec 30, 2024
pulisher
Dec 30, 2024

Geode Capital Management LLC Increases Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat

Dec 30, 2024
pulisher
Dec 29, 2024

Barclays PLC Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat

Dec 29, 2024
pulisher
Dec 27, 2024

Immunome (NASDAQ:IMNM) Shares Down 5.7%Time to Sell? - MarketBeat

Dec 27, 2024
pulisher
Dec 22, 2024

State Street Corp Sells 176,768 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World

Dec 22, 2024
pulisher
Dec 22, 2024

State Street Corp Cuts Stock Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat

Dec 22, 2024
pulisher
Dec 21, 2024

Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Analysts - Defense World

Dec 21, 2024
pulisher
Dec 21, 2024

Immunome, Inc. (NASDAQ:IMNM) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Dec 21, 2024
pulisher
Dec 21, 2024

Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of "Buy" from Analysts - MarketBeat

Dec 21, 2024
pulisher
Dec 19, 2024

Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Wellington Management Group LLP - Defense World

Dec 19, 2024
pulisher
Dec 19, 2024

Wellington Management Group LLP Has $2.06 Million Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat

Dec 19, 2024
pulisher
Dec 18, 2024

Immunome, Inc. (NASDAQ:IMNM) Sees Significant Decrease in Short Interest - Defense World

Dec 18, 2024
pulisher
Dec 16, 2024

Immunome, Inc. (NASDAQ:IMNM) Short Interest Update - MarketBeat

Dec 16, 2024
pulisher
Dec 15, 2024

Long Term Trading Analysis for (IMNM) - Stock Traders Daily

Dec 15, 2024
pulisher
Dec 12, 2024

Immunome, Inc. (NASDAQ:IMNM) Position Lifted by Charles Schwab Investment Management Inc. - Defense World

Dec 12, 2024
pulisher
Dec 12, 2024

Charles Schwab Investment Management Inc. Grows Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat

Dec 12, 2024
pulisher
Dec 11, 2024

Immunome: A Recently Acquired Lead Asset And A Small Market (NASDAQ:IMNM) - Seeking Alpha

Dec 11, 2024
pulisher
Dec 09, 2024

The Manufacturers Life Insurance Company Sells 1,437 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World

Dec 09, 2024
pulisher
Dec 09, 2024

Point72 Asset Management L.P. Boosts Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat

Dec 09, 2024
pulisher
Dec 07, 2024

Intech Investment Management LLC Takes $219,000 Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Dec 07, 2024
pulisher
Dec 06, 2024

Janus Henderson Group PLC Purchases 324,614 Shares of Immunome, Inc. (NASDAQ:IMNM) - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

Cerity Partners LLC Has $776,000 Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Dec 06, 2024
pulisher
Dec 04, 2024

Where are the Opportunities in (IMNM) - Stock Traders Daily

Dec 04, 2024
pulisher
Dec 02, 2024

Immunome Grants Stock Options to 15 New Hires in Workforce Expansion - StockTitan

Dec 02, 2024
pulisher
Nov 27, 2024

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference - The Bakersfield Californian

Nov 27, 2024
pulisher
Nov 27, 2024

President of Immunome Picks Up 24% More Stock - Simply Wall St

Nov 27, 2024
pulisher
Nov 26, 2024

Why Is Immunome Inc (NASDAQ: IMNM) Gaining? - Stocks Register

Nov 26, 2024
pulisher
Nov 26, 2024

Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Nov 26, 2024
pulisher
Nov 26, 2024

Immunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying Activity - Defense World

Nov 26, 2024
pulisher
Nov 25, 2024

Immunome's chief medical officer Robert Lechleider buys $149,799 in stock - Investing.com India

Nov 25, 2024
pulisher
Nov 25, 2024

Immunome's chief medical officer Robert Lechleider buys $149,799 in stock By Investing.com - Investing.com Australia

Nov 25, 2024
pulisher
Nov 25, 2024

Immunome Inc (IMNM) CEO Clay Siegall Increases Stake with Signif - GuruFocus.com

Nov 25, 2024
pulisher
Nov 25, 2024

Insider Buying: Robert Lechleider Acquires Shares of Immunome In - GuruFocus.com

Nov 25, 2024

Immunome Inc Stock (IMNM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
Cap:     |  Volume (24h):